1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Drugs In Development, 2022, provides an overview of the Female Contraception (Women's Health) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 6, 19 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 2 molecules, respectively.
Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Female Contraception - Overview
- Female Contraception - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Female Contraception - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Contraception - Companies Involved in Therapeutics Development
- Female Contraception - Drug Profiles
- Female Contraception - Dormant Projects
- Female Contraception - Discontinued Products
- Female Contraception - Product Development Milestones
- Featured News & Press Releases
- Oct 26, 2022: Phexxi mechanism of action article published in the Journal of Therapeutic Advances in Reproductive Health
- Oct 24, 2022: Mithra and Fuji announce approval of NEXTSTELLIS in Thailand
- Oct 06, 2022: Evofem Biosciences announces approval of Phexxi in Nigeria
- Sep 21, 2022: Mithra and Lotus announce approval of ALYSSA, an innovative oral contraceptive, in both Taiwan and Hong Kong
- Sep 19, 2022: Inventor of the year awarded to developer of Phexxi
- Sep 16, 2022: Large Commercial payer adds Phexxi to formulary for standard plans nationwide
- Aug 02, 2022: Nextstellis oral contraceptive has been nominated for the 2022 Prix Galien USA award for best pharmaceutical agent
- Aug 01, 2022: Mithra Announces Mayne Pharma’s New Direct-to-Consumer Campaign to Further Increase Awareness of NEXTSTELLIS in the U.S.
- Jul 29, 2022: Mayne Pharma and GoodRx announce new initiative to increase awareness of NEXTSTELLIS and expand access to birth control
- Jul 26, 2022: NEXTSTELLIS oral contraceptive now available in Australia
- Jul 26, 2022: Evofem's House Rules Campaign featuring Annie Murphy receives Significant Industry Recognition
- Jun 30, 2022: Evofem strengthens Phexxi intellectual property with new composition of matter patent from USPTO
- Jun 16, 2022: Phexxi prevented 99% of pregnancies per act of intercourse in a post hoc analysis of phase 3 AMPOWER Clinical Trial Data
- May 10, 2022: Evofem Biosciences to decrease cost of goods 45 percent through new partnership with Bora Pharmaceutical Services for the commercial manufacturing of Phexxi
- Apr 19, 2022: Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi from Evofem's Phase 3 AMPOWER Clinical Trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Female Contraception, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Female Contraception - Dormant Projects, 2022
- Female Contraception - Discontinued Products, 2022
- Number of Products under Development for Female Contraception, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adare Pharma Solutions
- Agile Therapeutics Inc
- Dare Bioscience Inc
- Evestra Inc
- Evofem Biosciences Inc
- Exeltis Pharmaceuticals Holding SL
- Hervana Ltd
- Hyundai Pharma Co Ltd
- InSilico Medicine
- Insud Pharma
- Lyndra Therapeutics Inc.
- MedinCell SA
- Micron Biomedical Inc
- Mithra Pharmaceuticals SA
- Mucommune LLC
- Myovant Sciences Ltd
- Navad Life Sciences Pte Ltd
- Noven Pharmaceuticals Inc
- Ohana BioSciences Inc
- Organon & Co
- Orion Biotechnology Canada Ltd
- Schrodinger Inc
- Teva Pharmaceutical Industries Ltd
- Viramal Ltd
- Yaso Therapeutics Inc
- YourChoice Therapeutics Inc
- ZabBio Inc
